Tag: Sutro
Antibody-drug Conjugate Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant...
Sutro Biopharma, a biotechnology company developing best-in-class antibody drug conjugate (ADC) and multi-specific antibody-based therapeutics for cancer therapy, including immune-oncology therapies has launched IND-enabling studies, including...
Sutro Biopharma and Celgene Expand Immuno-Oncology Product Discovery and Development Program
Sutro Biopharma, located in South San Francisco, and Celgene have entered into a strategic collaboration and option agreement designed to discover and develop multi-specific...
Sutro Collaborates with Merck and Recombinant Antibody Network
Earlier today, Sutro Biopharma, Inc, a biopharmaceutical company located in South San Francisco developing antibody drug conjugates and bispecific antibodies for targeted cancer therapies, and Merck Serono, the biopharmaceutical division of Merck KGaA (Darmstadt, Germany), the world’s oldest pharmaceutical and chemical company established in 1668 which operates as EMD Serono in the United States and Canada, announced that they will collaborate in developing Antibody-drug Conjugates or ADCs.
Dual-Warhead Takes Antibody Drug Conjugates a Step Further
Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing a cell-free protein synthesis technology, presented the first scientific data involving...
